ND-021 is under clinical development by Numab Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ND-021’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ND-021 is under development for the treatment of solid tumors including non small cell lung cancer (NSCLC). The drug candidate is a monovalent tri-specific antibody fragment specific for PD-L1, human serum albumin and a T cell costimulatory receptor fused in a single-chain (PD-L1/HSA/ Costim tri-specific scDb-scFv). It acts by targeting cells expressing programmed cell death ligand 1 (PDL1). It is administered through intravenous route.
Numab Therapeutics overview
Numab Therapeutics (Numab) is a developer of novel therapeutics for the treatment of severe diseases. The company’s pipeline products include ND021, ND009, ND023, ND026, ND023, ND026, and ND009, ND039, ND040 . Its ND009 is an anti-TNF antibody fragment that is being developed for inflammatory bowel disease, a chronic inflammation of the digestive tract that includes ulcerative colitis and Crohn’s disease. The company’s products are used in the treatment of inflammatory bowel disease, autoimmune disorders and metabolic disorders. It utilizes a proprietary antibody discovery and engineering technology to produce antibody Fv fragments. Numab is headquartered in Wadenswil, Zurich, Switzerland.
For a complete picture of ND-021’s drug-specific PTSR and LoA scores, buy the report here.